{"id":2133,"date":"2017-05-18T17:04:46","date_gmt":"2017-05-18T11:34:46","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2133"},"modified":"2021-07-24T12:56:46","modified_gmt":"2021-07-24T07:26:46","slug":"the-business-cocktail-23","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23","title":{"rendered":"Humira\u2019s patent; Teva laying off; GSK aims; Thermo acquires Patheon; J&#038; J&#8217;s Invokana"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fd0615f2462\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fd0615f2462\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23\/#Key_Humira_patent_goes_down_via_IPR%E2%80%94but_biosims_makers_shouldnt_celebrate_yet\" >Key Humira patent goes down via IPR\u2014but biosims makers shouldn&#8217;t celebrate yet<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23\/#Teva_laying_off_500_at_struggling_sterile_injectables_plant_in_Hungary\" >Teva laying off 500 at struggling sterile injectables plant in Hungary<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23\/#GlaxoSmithKline_aims_for_the_whole_consumer-health_portfolio_with_103B_Novartis_JV_buyout\" >GlaxoSmithKline aims for the whole consumer-health portfolio with $10.3B Novartis JV buyout<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23\/#Patheon_built_on_a_series_of_acquisitions_gets_acquired_by_Thermo_Fisher_in_72B_deal\" >Patheon, built on a series of acquisitions, gets acquired by Thermo Fisher in $7.2B deal<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23\/#Johnson_Johnsons_new_black-box_warning_on_Invokana\" >Johnson &amp; Johnson&#8217;s new black-box warning on Invokana<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Key_Humira_patent_goes_down_via_IPR%E2%80%94but_biosims_makers_shouldnt_celebrate_yet\"><\/span>Key Humira patent goes down via IPR\u2014but biosims makers shouldn&#8217;t celebrate yet<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">One of AbbVie\u2019s Humira patents bit the dust late Tuesday, marking a win for biosimilars makers. But they still have a long way to go before they\u2019ll really be able to celebrate. The U.S. Patent and Trademark Office\u2019s Patent Trial and Appeal Board (PTAB) handed down a verdict in Coherus BioSciences\u2019 favor, striking down AbbVie\u2019s \u2018135 methods patent on its top drug after an inter partes review. Barclays analysts had previously referred to the shield as \u201cone of the cornerstones of the Humira IP estate,\u201d which AbbVie needs to keep intact if it wants to keep copycats away from Humira\u2019s billions in revenue. AbbVie\u2019s \u2018619 patent, which is also being challenged through the IPR process, is still several months away from a decision, and all these IPR decisions are subject to appeal. Not only this, AbbVie has already prevailed in the IPR space with a few formulations patents, including some that expire in 2022. With those factors at play, either a biosimilar needs to wait till 2022, or try to work around the upheld patents.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Teva_laying_off_500_at_struggling_sterile_injectables_plant_in_Hungary\"><\/span>Teva laying off 500 at struggling sterile injectables plant in Hungary<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Teva is giving up on its sterile injectables plant in Godollo, Hungary, that halted production last year after the FDA found manufacturing failings. The generics maker is laying off hundreds of workers in the next few months and will sell or close the plant by the end of next year. A Teva spokesperson confirmed reports citing its plans to shed the facility on the outskirts of Budapest. About 500 workers are at risk of losing their jobs as the company winds down production at the site with the intent of selling or closing the plant by the end of 2018. The reduction is part of the company\u2019s global network operations strategy to align production capacity with market and patient demand globally. The announcement comes just weeks after Israeli media reported that the financially struggling and management-challenged drug maker was looking to cut up to 6,000 jobs.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"GlaxoSmithKline_aims_for_the_whole_consumer-health_portfolio_with_103B_Novartis_JV_buyout\"><\/span>GlaxoSmithKline aims for the whole consumer-health portfolio with $10.3B Novartis JV buyout<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">By March 2018, GlaxoSmithKline will have the option to buy out Novartis\u2019 stake in the pair\u2019s industry-leading consumer health JV. And it may already be getting prepared. The British drug maker is preparing for an \u00a38 billion ($10.3 billion) offer for its partner\u2019s 36.5% share. Industry watchers say Novartis could use this to help fund a mega takeover\u2014and word is, the potential target is AstraZeneca. The one-two deal punch may seem far-fetched, with Novartis pledging to eschew such enormous mergers. But the GSK consumer JV move lines up with the company&#8217;s previous statements, and its new CEO, Emma Walmsley, headed up that venture until her promotion in March. The news follows just a couple of days after one key GSK investor, Neil Woodford, walked away from the stock. Glaxo has said it aims to hang onto the business, and confirmed that strategy on the company\u2019s first-quarter earnings call.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Patheon_built_on_a_series_of_acquisitions_gets_acquired_by_Thermo_Fisher_in_72B_deal\"><\/span>Patheon, built on a series of acquisitions, gets acquired by Thermo Fisher in $7.2B deal<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Thermo Fisher Scientific is acquiring Patheon, which has been at the center of the consolidation that has swept through contract manufacturing in recent years, in a deal valued at $7.2 billion. Waltham, Massachusetts-based Thermo Fisher announced late Monday it would pay $35 a share for Patheon, a sum that amounts to about $5.2 billion, and assume another $2 billion in debt for the Durham, North Carolina-based CDMO. Thermo Fisher said it was a logical deal for a company that provides services and equipment to the biopharma industry, and offers it entry into the high-growth contract manufacturing business\u2014a market which it estimated to be worth about $40 billion. Patheon went public only last summer, but had revenues of about $1.9 billion in its last fiscal year, compared to the $18 billion in sales Thermo Fisher racked up in 2016. Thermo Fisher expects the deal to be \u201cimmediately and significantly accretive\u201d adding about $0.30 a share to its earnings in the first full year on the books. It also expects to realize about $90 million in cost savings by the third year and $30 million in adjusted operating income benefits.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Johnson_Johnsons_new_black-box_warning_on_Invokana\"><\/span>Johnson &amp; Johnson&#8217;s new black-box warning on Invokana<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">No company in a competitive market wants to land a serious new safety warning. But that\u2019s exactly the position Johnson &amp; Johnson is in with Type 2 diabetes med Invokana. The FDA recently concluded that the SGLT2 drug\u2014along with related combos Invokamet and Invokamet XR\u2014caused an increased risk of leg and foot amputations, and it mandated that J&amp;J update its labels accordingly. Regulators are requiring the New Jersey drug maker to add a black-box warning, the agency\u2019s most serious, to describe the risk. The FDA\u2019s decision follows a MedWatch safety alert from this time last year, which regulators issued after finding that patients in the Invokana arms of J&amp;J\u2019s two cardiovascular outcomes studies for the med were about twice as likely to experience amputations as were those in the placebo groups. J&amp;J&#8217;s Janssen unit, for its part, said in a statement that &#8220;patient safety is our highest priority&#8221; and that it was &#8220;working with FDA to include this information in the prescribing information&#8221; for Invokana.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Humira patent goes down via IPR\u2014but biosims makers shouldn&#8217;t celebrate yet One of AbbVie\u2019s Humira patents bit the dust late Tuesday, marking a win for biosimilars makers. But they still have a long way to go before they\u2019ll really be able to celebrate. The U.S. Patent and Trademark Office\u2019s Patent Trial and Appeal Board [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2134,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[812,903,900,901,2734,562,902],"industry":[17225],"therapeutic_areas":[17240,17227],"class_list":["post-2133","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-diabetes","tag-gsk","tag-humira","tag-ivokana","tag-johnson-and-johnson","tag-teva","tag-thermo-fisher","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Humira\u2019s patent; Teva laying off; GSK aims; Thermo acquires Patheon<\/title>\n<meta name=\"description\" content=\"One of AbbVie\u2019s Humira patents bit the dust late Tuesday, marking a win for biosimilars makers. But they still have a long way to go before...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Humira\u2019s patent; Teva laying off; GSK aims; Thermo acquires Patheon\" \/>\n<meta property=\"og:description\" content=\"One of AbbVie\u2019s Humira patents bit the dust late Tuesday, marking a win for biosimilars makers. But they still have a long way to go before...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-05-18T11:34:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022509\/1-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"648\" \/>\n\t<meta property=\"og:image:height\" content=\"269\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Humira\u2019s patent; Teva laying off; GSK aims; Thermo acquires Patheon","description":"One of AbbVie\u2019s Humira patents bit the dust late Tuesday, marking a win for biosimilars makers. But they still have a long way to go before...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23","og_locale":"en_US","og_type":"article","og_title":"Humira\u2019s patent; Teva laying off; GSK aims; Thermo acquires Patheon","og_description":"One of AbbVie\u2019s Humira patents bit the dust late Tuesday, marking a win for biosimilars makers. But they still have a long way to go before...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-05-18T11:34:46+00:00","article_modified_time":"2021-07-24T07:26:46+00:00","og_image":[{"width":648,"height":269,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022509\/1-2.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23","name":"Humira\u2019s patent; Teva laying off; GSK aims; Thermo acquires Patheon","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022509\/1-2.jpg","datePublished":"2017-05-18T11:34:46+00:00","dateModified":"2021-07-24T07:26:46+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"One of AbbVie\u2019s Humira patents bit the dust late Tuesday, marking a win for biosimilars makers. But they still have a long way to go before...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-23#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022509\/1-2.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022509\/1-2.jpg","width":648,"height":269},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/05\/09022509\/1-2-300x125.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GSK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Humira<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ivokana<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson and Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Teva<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Thermo Fisher<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Diabetes<\/span>","<span class=\"advgb-post-tax-term\">GSK<\/span>","<span class=\"advgb-post-tax-term\">Humira<\/span>","<span class=\"advgb-post-tax-term\">Ivokana<\/span>","<span class=\"advgb-post-tax-term\">Johnson and Johnson<\/span>","<span class=\"advgb-post-tax-term\">Teva<\/span>","<span class=\"advgb-post-tax-term\">Thermo Fisher<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on May 18, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on May 18, 2017 5:04 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2133"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2133\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2134"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2133"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2133"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}